Optimizing Cisplatin Delivery to Triple-negative Breast Cancer through Novel EGFR Aptamer-conjugated Polymeric Nanovectors
Lisa Agnello(Institute for Experimental Endocrinology and Oncology), Laura Cerchia(National Academies of Sciences, Engineering, and Medicine)
Cited by 2
Related Papers
Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers
|Scientific Reports|2017|93
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
|Journal of Experimental & Clinical Cancer Research|2021|82
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
|Journal of Experimental & Clinical Cancer Research|2020|70
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells
|Oncotarget|2015|67
Frontiers in Drug Design and Discovery
|Unknown|2006|49